Hosted on MSN
Cell-free RNA blood test identifies early-stage cancers, monitors treatment resistance and detects tissue damage
Stanford Medicine researchers have developed a blood test capable of detecting cancers, the ways cancer resists treatments and tissue injury caused by non-cancerous conditions. The new test analyzes ...
Scientists report that specific RNA patterns in blood may detect Parkinson’s disease early, opening a window for earlier care ...
RNA sequencing has emerged as a powerful supplement to DNA sequencing for Mendelian disease diagnosis, but clinical translation of diagnostic RNA-seq has not been widely achieved. Researchers at ...
VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...
Study aims to enhance colorectal cancer prevention by identifying polyp molecular signals, offering improved sensitivity over at-home DNA tests, which have limited ability to detect precancerous ...
A new liquid biopsy developed by researchers at the University of Chicago is offering a powerful new window into cancer’s earliest stages by flagging subtle shifts in the gut microbiome. Unlike ...
SAINT LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced the publication of their analytical validation study of ...
Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for ...
Stanford Medicine researchers have developed a blood test capable of detecting cancers, the ways cancer resists treatments and tissue injury caused by non-cancerous conditions. The new test analyzes ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted marketing authorization for Cepheid’s Xpert HCV test and GeneXpert Xpress System, the first ...
A single positive HIV viral load test often falsely identified HIV infection in people who were using long-acting cabotegravir (Apretude) for preexposure prophylaxis (PrEP), according to results from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback